



## **Collegium Announces the Appointment of Shirley Kuhlmann as General Counsel**

March 19, 2018

CANTON, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the appointment of Shirley Kuhlmann to the newly created position of Executive Vice President and General Counsel and Secretary, effective March 16, 2018. Ms. Kuhlmann will oversee all legal and compliance matters for the company.

"We are pleased to have Shirley join our leadership team at this exciting time," said Mike Heffernan, Collegium's CEO. "Shirley's previous role at Pepper Hamilton combined with her in-depth knowledge and understanding of Collegium, will bring immediate value as we execute our growth strategy."

Prior to joining Collegium, Ms. Kuhlmann was a Partner in the Health Sciences Department of Pepper Hamilton LLP, where she served as Collegium's outside counsel. Ms. Kuhlmann has over a decade of experience working with both private and public companies on a range of commercial and transactional matters, including financings, corporate governance and disclosure matters, and mergers and acquisitions and other business combination transactions. Ms. Kuhlmann holds a B.A. in Economics/Political Science from Columbia University and a J.D. from Emory University School of Law.

"I have been honored to represent Collegium as outside counsel, and I am very excited to be joining the team at this pivotal time in the Company's development. I look forward to working with this proven management team and executing on Collegium's mission to become the leader in responsible pain management," commented Ms. Kuhlmann.

### **About Collegium Pharmaceutical, Inc.**

Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative, differentiated products for patients suffering from pain.

### **About Xtampza ER**

Xtampza® ER is Collegium's first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Contact:

Alex Dasalla

[adasalla@collegiumpharma.com](mailto:adasalla@collegiumpharma.com)



Source: Collegium Pharmaceutical, Inc.